Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT07405736 2026-02-12

Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer

Phase 2 Not yet recruiting

124 enrolled

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT07406633 2026-02-12

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

Phase 2 Not yet recruiting

46 enrolled

GastrointestinalSarcoma

Digestive System Neoplasms, Gastrointestinal Stromal Tumors

NCT07397442 2026-02-11

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

19 enrolled

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT07402486 2026-02-11

A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer

Phase 2 Not yet recruiting

20 enrolled

Gastrointestinal

Rectal Neoplasms

NCT07403435 2026-02-11

Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC

Phase 2 Not yet recruiting

22 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07403877 2026-02-11

TORCH-OPTIMA

Phase 2 Not yet recruiting

114 enrolled

Gastrointestinal

Turcot syndrome, Colorectal Neoplasms

NCT07391826 2026-02-06

Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX

Phase 2 Not yet recruiting

48 enrolled

Gastrointestinal

Stomach Neoplasms

NCT07394192 2026-02-06

PKUCH- R11

Phase 2 Not yet recruiting

44 enrolled

Gastrointestinal

Rectal Neoplasms

NCT07224022 2026-02-04

NACho

Phase 2 Not yet recruiting

24 enrolled

Gastrointestinal

Colonic Neoplasms

NCT07385664 2026-02-04

FAIR

Phase 2 Not yet recruiting

66 enrolled

Gastrointestinal

Resectable Esophageal Cancer

NCT07381400 2026-02-03

Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)

Phase 2 Not yet recruiting

128 enrolled

Gastrointestinal

Rectal Neoplasms

NCT07383285 2026-02-03

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

Phase 2 Not yet recruiting

106 enrolled

Gastrointestinal

Rectal Neoplasms Malignant

NCT07381777 2026-02-02

IMMUNOSTAR

Phase 2 Not yet recruiting

270 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer (LARC)

NCT07376876 2026-01-29

Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy

Phase 2 Not yet recruiting

73 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Anastomotic Leak

NCT07369791 2026-01-28

NOBLE

Phase 2 Not yet recruiting

76 enrolled

Gastrointestinal

Advanced Biliary Tract Cancer(BTC)

NCT07363356 2026-01-23

Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer

Phase 2 Not yet recruiting

56 enrolled

Gastrointestinal

Hepatocellular Carcinoma Resectable

NCT07359456 2026-01-22

COLIBRI-GI

Phase 2 Not yet recruiting

130 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07354919 2026-01-21

AxeCan

Phase 2 Not yet recruiting

34 enrolled

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07209215 2026-01-20

ULTIMATE

Phase 2 Not yet recruiting

200 enrolled

Gastrointestinal

Rectal Neoplasms

NCT07314372 2026-01-20

FAD-HCC-001

Phase 2 Not yet recruiting

86 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT07351513 2026-01-20

A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma

Phase 2 Not yet recruiting

94 enrolled

Gastrointestinal

Unresectable Hepatocellular Carcinoma

NCT07351591 2026-01-20

A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers

Phase 2 Not yet recruiting

88 enrolled

Gastrointestinal

Advanced Biliary Tract Cancer(BTC)

NCT07353268 2026-01-20

Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.

Phase 2 Not yet recruiting

76 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07353827 2026-01-20

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Phase 2 Not yet recruiting

36 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06855225 2026-01-14

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Phase 2 Not yet recruiting

29 enrolled

Gastrointestinal

Liver Neoplasms

NCT07337551 2026-01-13

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

Phase 2 Not yet recruiting

20 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07333287 2026-01-12

A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.

Phase 2 Not yet recruiting

38 enrolled

Gastrointestinal

Pancreatic Cancer Liver Metastases

Clinical Trials

SAMe in Prevention of Oxaliplatin-associated Liver Injury

An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies

FAPDIG

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer

TRIUNITE-07

The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities

PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer

Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression

PEMIGIST

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

RESET C2

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer

IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer

Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC

TORCH-OPTIMA

Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX

PKUCH- R11

NACho

FAIR

Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

IMMUNOSTAR

Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy

NOBLE

Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer

COLIBRI-GI

AxeCan

ULTIMATE

FAD-HCC-001

A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma

A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers

Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.